Characteristic | Controls, n = 10 | DMARD, n = 24 | Biologics, n = 17 | p |
---|---|---|---|---|
Age, yrs* | 55.7 ± 4.5 | 59.0 ± 2.2 | 53.7 ± 2.7 | 0.278 |
Male/female, n†† | 0:10 | 2:22 | 4:13 | 0.144 |
RA duration, mos† | — | 79.5 ± 108.3 | 50.1 ± 73.5 | 0.643 |
Anti-CCP, u/ml† | — | 102.9 ± 19.2 | 44.9 ± 45.3 | 0.104 |
RF, u/ml† | — | 56.3 ± 26.4 | 90.0 ± 31.4 | 0.672 |
DAS28-ESR† | — | 4.5 ± 1.0 | 2.9 ± 1.6 | 0.002 |
MTX, mg† | — | 8.2 ± 1.7 | 8.6 ± 1.8 | 0.434 |
↵† : Wilcoxon rank sum test.
↵†† : Fisher’s exact test.
↵* : Kruskal-Wallis test. DMARD: disease-modifying antirhreumatic drug; RA: rheumatoid arthritis; DAS-28-ESR: 28-joint Disease Activity Score using erythrocyte sedimentation rate; MTX: methotrexate; anti-CCP: anticyclic citrullinated peptide antibodies; RF: rheumatoid factor.